Clinical Trial Update: 6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Open-label Phase 3 study of lumiracoxib 200 mg once daily in primary knee osteoarthritis or rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis
• Rheumatoid Arthritis

Drugs mentioned

• Lumiracoxib (Lumiracoxib)

Snippet

Sponsor: Novartis | Conditions: Osteoarthritis, Rheumatoid Arthritis | Phase 3 | Status: COMPLETED